比较数字乳腺断层合成与数字乳腺X线筛查的随机对照试验中间隔癌与后续轮次筛查检出癌
To-Be随机对照试验纳入28 749名女性,比较数字乳腺断层合成(DBT)与数字乳腺X线(DM)筛查,22 306名女性2年后返回行后续筛查。间隔癌率DBT组1.4/1000 vs DM组2.0/1000(P=0.20),后续轮次筛查检出癌率DBT组8.1/1000 vs DM组9.1/1000(P=0.43),肿瘤病理特征分布无差异,提示DBT筛查获益未以牺牲下游筛查表现为代价。
要点
- 间隔癌率DBT组1.4/1000 vs DM组2.0/1000,差异未达统计学显著(P=0.20)。
- 后续轮次筛查检出癌率DBT组8.1/1000 vs DM组9.1/1000,差异未达统计学显著(P=0.43)。
- 间隔癌与后续筛查检出癌的肿瘤病理特征分布在DBT与DM组间无差异。
核心结论
- 最初接受DBT筛查与DM筛查的女性在间隔癌率、后续轮次筛查检出癌率及肿瘤特征上无差异;分析提示在人群筛查项目中,DBT筛查的获益未以更差的下游筛查表现指标为代价。
研究设计与样本
- To-Be随机对照试验,比较DBT与DM在组织性乳腺癌筛查中的结果;共纳入28 749名女性,其中22 306名女性2年后返回行后续DBT筛查(最初经DBT筛查11 201名、经DM筛查11 105名);采用Z检验、t检验和χ2检验评估率、均值及病理肿瘤特征分布的差异,并计算率比的相对危险度(RR)及95%CI。
诊断标准与关键数值
- 间隔癌率:DBT组1.4/1000(20/14 380;95%CI:0.9,2.1)vs DM组2.0/1000(29/14 369;95%CI:1.4,2.9;P=0.20)。
- 后续轮次筛查检出癌率:最初DBT筛查组8.1/1000(95%CI:6.6,10.0)vs DM筛查组9.1/1000(95%CI:7.4,11.0;P=0.43)。
- 间隔癌RR:DBT vs DM为0.69(95%CI:0.39,1.22;P=0.20)。
- 后续筛查检出癌RR:最初DBT筛查 vs DM筛查为0.89(95%CI:0.67,1.19;P=0.43)。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
Background Prevalent digital breast tomosynthesis (DBT) has shown higher cancer detection rates and lower recall rates compared with those of digital mammography (DM). However, data are limited on rates and histopathologic tumor characteristics of interval and subsequent round screen-detected cancers for DBT. Purpose To follow women randomized to screening with DBT or DM and to investigate rates and tumor characteristics of interval and subsequent round screen-detected cancers. Materials and Methods To-Be is a randomized controlled trial comparing the outcome of DBT and DM in organized breast cancer screening. The trial included 28 749 women, with 22 306 women returning for subsequent DBT screening 2 years later (11 201 and 11 105 originally screened with DBT and DM, respectively). Differences in rates, means, and distribution of histopathologic tumor characteristics between women prevalently screened with DBT versus DM were evaluated with Z tests, t tests, and χ2 tests. Relative risk (RR) with 95% CIs was calculated for the cancer rates. Results Interval cancer rates were 1.4 per 1000 screens (20 of 14 380; 95% CI: 0.9, 2.1) for DBT versus 2.0 per 1000 screens (29 of 14 369; 95% CI: 1.4, 2.9; P = .20) for DM. The rates of subsequent round screen-detected cancer were 8.1 per 1000 (95% CI: 6.6, 10.0) for women originally screened with DBT and 9.1 per 1000 (95% CI: 7.4, 11.0; P = .43) for women screened with DM. The distribution of tumor characteristics did not differ between groups for either interval or subsequent screen-detected cancer. The RR of interval cancer was 0.69 (95% CI: 0.39, 1.22; P = .20) for DBT versus DM, whereas RR of subsequent screen-detected cancer for women prevalently screened with DBT versus DM was 0.89 (95% CI: 0.67, 1.19; P = .43). Conclusion Rates of interval or subsequent round screen-detected cancers and their tumor characteristics did not differ between women originally screened with digital breast tomosynthesis (DBT) versus digital mammography. The analysis suggests that the benefits of prevalent DBT screening did not come at the expense of worse downstream screening performance measures in a population-based screening program. © RSNA, 2021 Online supplemental material is available for this article. See also the editorial by Taourel in this issue.
引用
- Hofvind S, Moshina N, Holen ÅS, et al. Interval and Subsequent Round Breast Cancer in a Randomized Controlled Trial Comparing Digital Breast Tomosynthesis and Digital Mammography Screening. Radiology. 2021. PMID: 33973840. doi:10.1148/radiol.2021203936
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。